Management of Diastolic Heart Failure
AbstractThe diastolic heart failure also referred to as heart failure with preserved left ventricular systolic function (preserved ejection fraction). The difference between systolic and diastolic HFs is a pathophysiological one and isolated forms of left ventricular dysfunction are rarely observed. In diastolic HF left ventricular systolic function is normal or only slightly impaired, and the typical manifestations of HF result from increased filling pressure caused by impaired relaxation and compliance of the left ventricle. The management should include antihypertensive treatment, maintenanceof the sinus rhythm, prevention of tachycardia, venous pressure reduction, prevention of myocardial ischemia and prevention of diabetes mellitus. Treatment of diastolic HF is aimed to stop the progression of the disease, relieve its symptoms, eliminate exacerbations and reduce the mortality. The predisposing factors for diastolic dysfunction include elderly age, female sex, obesity, coronary artery disease, hypertension and diabetes mellitus. The European Society of Cardiology specifies the type of therapy in diastolic HF based on: angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, non dihydropyridine calcium channel blockers, diuretics.
Grossman W. Defining diastolic dysfunction. Circulation. 2000; 101: 2020-2021.
Van Heerebeek L, Borbly A, Niessen HW et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation, 2006; 113: 774-781.
Opolski G eds. Kardiologia. 1st Ed. Urban & Partner, Wroclaw 2003.
Nagueh SF, Appleton CP, Gillebert TC et al. Recommendation for the evaluations of the left ventricular diastolic function by echocardiography. Eur J Echocardiogr, 2009; 10: 165-193.
Aurigemma GP. Diastolic heart failure: A common and lethal codition by any name. N Engl J Med, 2006; 355: 308-310.
Jessup M, Abraham WT, Casey DE et al. ACCF/AHA guidelines for the diagnosis and management of heart failure in adult: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation, 2009; 119: 1977-2016.
Gandhi SK, Powers JC, Nomeir AM et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med, 2001; 244: 17-22.
Dahlof B, Devereux RB, Kjedsen SE et al. Cardiovascular morbidity and mortality in the Losartan intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial againts atenolol. Lancet, 2002; 359: 995-1003.
Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chonic heart failure and preserved left ventricular ejection fraction: The CHARM-Preserved Trial. Lancet, 2003;362: 771-781.
Cleland JGF, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J, 2006; 27: 2338-2345.
Solomon SD, Janardhanan R, Verma A et al. ;for the valsartan in Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: A randomised trial. Lancet, 2007; 369: 2079-2087.
Kostis JB, Davis BR, Cutler J et al. Prevention on heart failure by antihypertensive drug treatment in older person with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA, 1997; 278: 212-216.
Ofili EO, Cohen JD, St. Vrain J et al. Effect of treatment of isolated systolic hypertension on left ventricular mass. JAMA. 1998; 278-780.
Bergstorm A, Adersson B, Edner M et al. effect of carvedilol on diastolic dysfunction in patients with diastolic heart failure and preserved systolic function. Result of the Swedih Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail, 2004; 6: 453-461.
Tendera M, Schneeweiss A, Bartoszewski A et al. The acute response of the left ventricular filling dynamics to intravenous verapamil predicts the changes in exercise tolerance after oral verapamil therapy in patients with hypertropic cardiomyopathy, Eur Heart J. 1993; 14: 410-415.
Ghio S, Magrini G Serio A et al. SENIORS investigators. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: Results of the SENIORS echocardiographic substudy. Eur Heart J, 2006; 27:562-568.
The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med, 1997; 336: 325-533.
Kramer K, Kirkman P, Kitzman D et al. Flash pulmonary edema: association with hypertension and reoccurrence despite coronary revascularization. Am Heart J, 2000; 40: 451-455.
Fukuda H, Sane D, Brucks S et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure. A preliminary report. Circulation, 2005; 112: 357-363.
PDF downloads: 54
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).